EMA Authorised: Zejula (niraparib (tosilate monohydrate)) — GlaxoSmithKline Trading Services Limited

View source ↗

Summary

The EMA authorised Zejula for fallopian tube neoplasms, peritoneal neoplasms, and ovarian neoplasms. GlaxoSmithKline Trading Services Limited is the marketing a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Neoplasms
• Ovarian Neoplasms
• Peritoneal Neoplasms

Drugs mentioned

• Zejula (Niraparib)

Snippet

Status: Authorised. Therapeutic area: Fallopian Tube Neoplasms;Peritoneal Neoplasms;Ovarian Neoplasms. MAH: GlaxoSmithKline Trading Services Limited. Decision date: 17/11/2025. Orphan medicine